Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090977 | 0.88 | F10 (0.68) | F10KLK1 | |
| SCHEMBL5088851 | 0.87 | F10 (0.61) | F10KLK1 | |
| SCHEMBL5088843 | 0.85 | F10 (0.67) | F10KLK1 | |
| SCHEMBL5088821 | 0.85 | F10 (0.58) | F10KLK1 | |
| SCHEMBL5092554 | 0.85 | F10 (0.62) | F10KLK1 | |
| SCHEMBL5099270 | 0.83 | F10 (0.62) | F10KLK1 | |
| SCHEMBL4900354 | 0.82 | F10 (0.65) | F10KLK1 | |
| SCHEMBL5090992 | 0.82 | F10 (0.61) | F10KLK1 | |
| SCHEMBL5088795 | 0.82 | F10 (0.63) | F10KLK1 | |
| SCHEMBL5090966 | 0.82 | F10 (0.61) | F10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419979-B2 | Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | claimed |
| JP-2007517870-A | — | — | 2007-07-05 | — | — | JP | claimed |
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| EP-1706120-A1 | NEW DERIVATIVES OF 6- 4 4 - 1 H - INDOLE-2-SULPHONYL)-PIPERA ZIN-1-CARBONYL-PHENYL PYRADIZIN-3-ONE | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005065688-A1 | NEW DERIVATIVES OF 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | claimed |
| US-7419979-B2 | Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | disclosed |
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| CN-1905883-A | Novel derivatives of 6- { 4- [ 4- (1H-indole-2-sulfonyl) -piperazine-1-carbonyl-phenyl ] } pyridazin-3-one | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | HTR7, TRPC7, HRH4 | F10 803/4885KLK1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.